Information on how much funding has been provided to prevent and tackle Group B Strep infection among pregnant women over the last five years is not collected centrally.

The Government has made clear that maternity care is a priority and on 13 November 2015 announced an ambition to reduce by 50% stillbirths, neonatal deaths, maternal deaths and neonatal brain injuries by 2030. This includes harm and death caused by Group B Streptococcus (GBS).

A range of work addressing GBS is being taken forward by the Department of Health and Public Health England with a range of partner organisations. This includes:

― Monitoring developments on GBS vaccines and undertaking a grant-funded study to assess the potential impact of a maternal immunisation programme.

― An audit in partnership with the London School of Hygiene and Tropical Medicine and supported by the Royal College of Midwives, recently carried out by the Royal College of Obstetricians and Gynaecologists (RCOG). This examined current practice in preventing early onset neonatal GBS disease by investigating the implementation of the RCOG Green-top guideline on preventing the disease. The last of two reports was published on 29 January 2016 and has made recommendations for improvements in care in the prevention of early-onset GBS disease.

― The National Institute of Health Research has approved funding for a study on accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors (GBS2). The study commenced in May 2016.

The Department is also convening two half day workshops with leading experts from a wide range of organisations, including the RCPG and Gynaecologists, the Royal College of Paediatrics and Child Health and the charity Group B Strep Support to discuss research evidence gaps in relation to GBS.

Information on how much funding has been provided to prevent and tackle Group B Strep infection among pregnant women over the last five years is not collected centrally.

The Government has made clear that maternity care is a priority and on 13 November 2015 announced an ambition to reduce by 50% stillbirths, neonatal deaths, maternal deaths and neonatal brain injuries by 2030. This includes harm and death caused by Group B Streptococcus (GBS).

A range of work addressing GBS is being taken forward by the Department of Health and Public Health England with a range of partner organisations. This includes:

― Monitoring developments on GBS vaccines and undertaking a grant-funded study to assess the potential impact of a maternal immunisation programme.

― An audit in partnership with the London School of Hygiene and Tropical Medicine and supported by the Royal College of Midwives, recently carried out by the Royal College of Obstetricians and Gynaecologists (RCOG). This examined current practice in preventing early onset neonatal GBS disease by investigating the implementation of the RCOG Green-top guideline on preventing the disease. The last of two reports was published on 29 January 2016 and has made recommendations for improvements in care in the prevention of early-onset GBS disease.

― The National Institute of Health Research has approved funding for a study on accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors (GBS2). The study commenced in May 2016.

The Department is also convening two half day workshops with leading experts from a wide range of organisations, including the RCPG and Gynaecologists, the Royal College of Paediatrics and Child Health and the charity Group B Strep Support to discuss research evidence gaps in relation to GBS.